Company Filing History:
4 out of 1,217 
1 out of 9 Years Active: 1992-2022
Title: **Phil Skolnick: Innovator in Neuropharmacology**
Introduction
Phil Skolnick, based in Potomac, MD, is a distinguished figure in the field of neuropharmacology. With a remarkable record of five patents to his name, Skolnick has contributed significantly to medical science, particularly in the treatment of conditions related to cannabinoid use and neuropsychopharmacological disorders.
Latest Patents
Among his latest innovations are notable patents that address pressing medical challenges. One of his significant inventions is the patent titled "Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist." This patent outlines formulations and methods that involve administering a CB1 antagonist to reverse one or more symptoms of cannabinoid hyperemesis syndrome (CHS).
Another impactful patent is for "Partial agonists of the strychnine insensitive glycine modulatory site." This invention provides a method for treating neuropsychopharmacological disorders linked to excessive activation of the N-methyl-D-aspartate receptor complex. It includes the use of compounds that act as partial agonists at specific receptor sites, showcasing Skolnick's innovative approach to treatment.
Career Highlights
Throughout his career, Phil Skolnick has made significant strides in pharmaceutical research and development. He has been involved with agencies like the United States of America as represented by the Department of Health, as well as private sectors such as Opiant Pharmaceuticals, Inc. His work has been pivotal in advancing therapeutic options for complex medical conditions.
Collaborations
Skolnick has worked alongside esteemed colleagues including Ramon Trullas and Kenneth Alan Jacobson. These collaborations have fostered advancements in neuropharmacology, enhancing the impact of their collective research efforts and leading to the development of innovative treatments.
Conclusion
Phil Skolnick's contributions to the field of neuropharmacology are reflective of his dedication to innovation and improvement in medical treatments. With multiple patents and ongoing research, his work continues to pave the way for future advancements in healthcare.